Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (171-180 of 259) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Breast Cancer Research and Treatment|May 29, 2019
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trialMatteo Lambertini, Christine Campbell, Richard D Gelber, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAmir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
Critical Reviews in Oncology/Hematology|August 10, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabVeronique Debien, Guilherme Nader Marta, Elisa Agostinetto, et al.
Breast Cancer Research : BCR|May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialLynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.
Cancer|October 19, 2018
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2018
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 TrialYoussef H Zeidan, Joyce G Habib, Lieveke Ameye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialHatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
British Journal of Cancer|September 1, 2022
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO studyGuilherme Nader-Marta, Véronique Debien, Daniel Eiger, et al.
Pageof 26

Showing results (171-180 of 259) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Breast Cancer Research and Treatment|May 29, 2019
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trialMatteo Lambertini, Christine Campbell, Richard D Gelber, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAmir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
Critical Reviews in Oncology/Hematology|August 10, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabVeronique Debien, Guilherme Nader Marta, Elisa Agostinetto, et al.
Breast Cancer Research : BCR|May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialLynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.
Cancer|October 19, 2018
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2018
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 TrialYoussef H Zeidan, Joyce G Habib, Lieveke Ameye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialHatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
British Journal of Cancer|September 1, 2022
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO studyGuilherme Nader-Marta, Véronique Debien, Daniel Eiger, et al.
Pageof 26